MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia (vol 97, pg 63, 2018)

Zhang Xiaolu; Li Bingnan; Yu Jingya; Dahlstrom Jenny; Anh Nhi Tran; Bjorkholm Magnus; Xu Dawei

首页> 外文期刊>Annals of hematology >MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia (vol 97, pg 63, 2018)

【24h】

MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia (vol 97, pg 63, 2018)

机译：在急性髓性白血病（Vol 97，PG 63,2018）中，FLT3抑制剂的Interogerase依赖性抑制剂的依赖性下调

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of hematology》 |2018年第7期|共1页
作者
Zhang Xiaolu; Li Bingnan; Yu Jingya; Dahlstrom Jenny; Anh Nhi Tran; Bjorkholm Magnus; Xu Dawei;
展开▼
作者单位

Karolinska Univ Hosp Solna Dept Med Ctr Hematol SE-17176 Stockholm Sweden;

Karolinska Univ Hosp Solna Dept Med Ctr Hematol SE-17176 Stockholm Sweden;

Karolinska Univ Hosp Solna Dept Med Ctr Hematol SE-17176 Stockholm Sweden;

Karolinska Univ Hosp Solna Dept Med Ctr Hematol SE-17176 Stockholm Sweden;

Karolinska Inst SE-17176 Stockholm Sweden;

Karolinska Univ Hosp Solna Dept Med Ctr Hematol SE-17176 Stockholm Sweden;

Karolinska Univ Hosp Solna Dept Med Ctr Hematol SE-17176 Stockholm Sweden;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia (vol 97, pg 63, 2018) [J] . Zhang Xiaolu, Li Bingnan, Yu Jingya, Annals of hematology . 2018,第7期

机译：在急性髓性白血病（Vol 97，PG 63,2018）中，FLT3抑制剂的Interogerase依赖性抑制剂的依赖性下调
2. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial [J] . Jonas Brian A., Cortes Jorge E., Khaled Samer K., Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：单药剂Quizartinib，一种有效和选择性FLT3抑制剂（FLT3i），患者（PTS）的疗效和安全性，具有FLT3 - 内部串联复制（FLT3-ITD） - 突变复发/难治（R / R）急性髓性白血病（AML ）注册全球，第3阶段，随机控制量子-R试验
3. Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial [J] . Cortes Jorge E., Khaled Samer K., Martinelli Giovanni, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单药剂Quizartinib（Q），有效和选择性FLT3抑制剂（FLT3I），患者（PTS）的疗效和安全性，具有FLT3 - 内部串联复制（FLT3-ITD） - 矫正复发/难以（R / R）急性髓样 Leukemia（AML）注册了全球第3阶段，随机控制量子-R试验
4. Tandem mass spectrometry characterizes the related substances of second generation FLT3 inhibitor Quizartinib, anti cancer compound for myeloid leukemia [C] . Saravanan Subramaniyan, Arvind Thyagarajan, Rampriya Uthayakumar, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：串联质谱表征第二代FLT3抑制剂Quizartinib的相关物质，用于髓性白血病的抗癌化合物
5. Comparison of FLT3 Inhibitors with the Standard Treatment for FLT3-ITD Mutated Acute Myeloid Leukemia [D] . Argetsinger, Stephanie. 2018

机译：FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
6. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia [O] . Xiaolu Zhang, Bingnan Li, Jingya Yu, -1

机译：FLT3抑制剂对MYC依赖的端粒酶下调是其对急性髓细胞白血病的治疗功效所必需的
7. MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin [O] . Katja Seipel, Miguel A.T. Marques, Corinne Sidler, 2018

机译：MDM2和FLT3抑制剂治疗FLT3-ITD急性髓性白血病，NVP-HDM201和中豚鼠的特异性和疗效

MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia (vol 97, pg 63, 2018)

著录项

相似文献

相关主题

期刊订阅